Cargando…
Conclusions of the expert panel: importance of erlotinib as a second-line therapeutic option
During the Experts Meeting on Lung Cancer, participants emphasized the usefulness of erlotinib as second-line therapy for lung cancer. They noted that, although there are no comparative studies, erlotinib could be as effective as docetaxel and pemetrexed in second-line therapy. Regarding the toxicit...
Autor principal: | Castagnari, Aldo |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2559800/ https://www.ncbi.nlm.nih.gov/pubmed/18831720 |
Ejemplares similares
-
The Human in the Middle: Artificial Intelligence in Health Care Summary Proceedings Symposium Presentation and Reactor Panel of Experts Thomas Jefferson University December 10, 2019
por: Clarke, Janice, et al.
Publicado: (2021) -
The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report
por: Grigorian-Shamagian, Lilian, et al.
Publicado: (2023) -
Panel session and conclusions
por: Dorigo, Tommaso, et al.
Publicado: (2018) -
First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view
por: Thatcher, Nicholas
Publicado: (2008) -
A mixture of feature experts approach for protein-protein interaction prediction
por: Qi, Yanjun, et al.
Publicado: (2007)